Fortress Biotech Inc. 9.3... (FBIOP)

NasdaqCM: FBIOP · リアルタイム株価 · USD

18.20

-0.06 (-0.33%)

終値時点： Aug 19, 2026, 8:00 PM

18.18

-0.14%

時間外: 5:09 PM

-0.33% (1D)

データがありません

買気配	18.16
時価総額	n/a
売上高（TTM）	68.47M
純利益（TTM）	103.37M
ベータ	1.21
EPS（TTM）	-0.86
PER（TTM）	n/a
予想PER	n/a
PBR（TTM）	3.69
PSR（TTM）	n/a
Earnings Date	n/a

売気配	18.18
出来高	11,493
平均出来高（20日）	21,588
始値	18.23
前日終値	18.26
当日レンジ	18.05 - 18.34
52週レンジ	6.27 - 21.43
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	2024年6月14日

FBIOPについて

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Nov 14, 2017

従業員数 78

上場取引所 NasdaqCM

ティッカー FBIOP

ウェブサイト https://www.fortressbiotech.com

企業情報の全文

業績

2025年のFortress Biotech 9.375% Series A Cumulative Redeemable Perpetual Preferred Stockの売上高は63.26Mで、前年の57.67Mから9.69%の増加でした。利益は6.82Mで、-114.82%の減少でした。

財務諸表

ニュース

5日前 · Moby

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call

6日前 · Motley Fool

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

1週間前 · MarketBeat

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Exe...

1か月前 · Simply Wall St.

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Re...

5か月前 · TipRanks

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Re...

2ページ中1ページ

Fortress Biotech Inc. 9.3... (FBIOP)

FBIOPについて

業績

決算サプライズ

Why Price Moved